Alosa Health

Alosa Health runs various academic detailing programs. Since 2005, Alosa Health-trained academic detailers have conducted almost 20,000 educational outreach visits with over 5,000 prescribers, covering 23 different clinical modules.

---

Boston, Massachusetts, USA
Non-profit organization

---

​Program Clinical Topics
Atrial Fibrillation | COPD | Smoking Cessation | Elder Abuse | Dementia | Heart Failure | Hypertension | Incontinence | Lipids | Pain Management | Opioids | Diabetes | PrEP/HIV

---

Modules & Programming

---

clinical modules

• Atrial Fibrillation (CME credit from HMS through July 2018)
• COPD and Smoking Cessation (CME credit from HMS through July 2020)
• Elder Abuse and Dementia (CME credit from HMS through April 2020)
• Heart Failure (CME credit from HMS through December 2018)
• Hypertension (CME credit from HMS through November 2019)
• Incontinence (CME credit from HMS through April 2018)
• Lipids (CME credit from HMS through July 2019)
• Managing pain in the elderly (CME credit from HMS through December 2017)
• Pre-exposure Prophylaxis (PrEP) (CME credit from HMS through March 2020)
• Opioids (CME credit from MMS through March 2018)
• Type 2 diabetes (CME credit from HMS through April 2019)

For a complete, up to date listing of Alosa's offerings, please visit their program site.

Resources & Partnerships

---

TRAININGS

• NaRCAD has trained Alosa staff via our 2-Day Academic Detailing Techniques Course. Alosa also offers its own academic detailing training.​

presentations & publications

• Alosa staff will present at the next NaRCAD-hosted International Conference on Academic Detailing Series via a breakout session on materials development.

Alosa Publications via AlosaHealth.org:

• TOPCARE Intervention Shows Promise For Opioid Prescription Monitoring
• Educational Outreach to Opioid Prescribers: The Case for Academic Detailing
• The Case for Academic Detailing with Nurse Practitioners
• Academic Detailing: “Marketing” the Best Evidence to Clinicians
• Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy
• The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform
• Forbidden and Permitted Statements about Medications – Loosening the Rules